What’s Shifting and Why It Matters

Supplier Controls Under QMSR

by T. King

Why Suppliers Matter More Than Ever

In a global supply chain, your product is only as reliable as the partners who build it. QMSR makes that official.
The FDA now expects manufacturers to treat suppliers as extensions of their own quality system — with proof of ongoing control.

The New Expectations

  1. Risk-Based Supplier Qualification – Assess suppliers by impact on product safety and performance.
  2. Formal Quality Agreements – Document responsibilities, communication, and change notification processes.
  3. Continuous Performance Monitoring – Track metrics like on-time delivery, non-conformances, and CAPA closure rates.
  4. Re-Evaluation – Conduct periodic risk-based re-assessments.

What FDA Will Expect to See

During inspections, expect requests for:

  • Supplier audit reports.
  • Supplier performance data and trend analysis.
  • CAPA records initiated due to supplier issues.
  • Documented management review of supplier performance.

How to Build a Modern Supplier Program

  • Develop a supplier risk matrix and tier structure.
  • Use standardized qualification and monitoring templates.
  • Automate tracking of metrics and review cycles.
  • Include supplier performance in annual management review.

Pro Tip

Invite key suppliers to joint CAPA and risk reviews. Collaboration reduces errors and builds trust that auditors can see.

The Compliance Insight Edge

We’ve built and audited supplier programs for medical device manufacturers across three continents. Our consultants understand what FDA expects and how to translate that into practical, maintainable systems that fit your business size and risk profile.

Start your supplier program refresh with us — and enter 2026 knowing your network is QMSR-ready. Contact us today!

T. King served as a regulatory compliance writer and content contributor at Compliance Insight, Inc., where she authored over 100 articles covering FDA compliance, GMP regulations, medical device requirements, pharmaceutical quality systems, and life sciences regulatory affairs. Her work supported Compliance Insight's mission of making FDA regulatory guidance accessible and actionable for life science professionals.